The mammalian target of rapamycin complex 1 (mTORC1) is well-established as a master regulator of cellular growth and metabolism, responding dynamically to nutrient availability, energy status, and growth signals. Central to this process is the Rag GTPase complex, which governs mTORC1 localization to lysosomal membranes where it becomes activated. Until now, the complexity of signaling events upstream to Rag GTPases and how lysosomal lipid dynamics influence this pathway remained poorly understood. The team led by Picot et al. bridges this gap by demonstrating that the turnover of specific phosphoinositides within lysosomal membranes dictates Rag GTPase activity, acting as a molecular rheostat for mTORC1 signaling and muscle development.

At the heart of these findings lies phosphoinositides—specialized phosphorylated lipids that regulate diverse cellular processes by virtue of their spatial and temporal distribution on membranes. Lysosomal phosphoinositides, in particular, have been enigmatic given the organelle’s traditional classification as the cellular degradation hub. The study overturns this view, showcasing lysosomes as dynamic signaling platforms where rapid phosphoinositide turnover finely tunes muscle cellular anabolic pathways. Utilizing advanced lipidomic analyses coupled with sophisticated genetic perturbations in murine models, researchers pinpoint dynamic changes in phosphatidylinositol 3-phosphate (PI3P) and phosphatidylinositol 3,5-bisphosphate (PI(3,5)P2) levels as decisive factors modulating Rag GTPase localization and activity.

Mechanistically, the research unravels an intricate feedback loop where phosphoinositide-modifying enzymes coordinate lysosomal membrane lipid composition. These changes alter binding affinities of Rag GTPase regulators, thereby finely adjusting mTORC1 recruitment and activation. Disrupting this lipid turnover process uncouples Rag GTPase activity from nutrient cues, resulting in blunted mTORC1 signaling and impaired muscle hypertrophy. Conversely, enhancing lysosomal phosphoinositide cycling boosts mTORC1 output and fosters robust muscle growth, establishing causation beyond correlation.

Excitingly, the study reveals muscle-specific nuances in lysosomal lipid signaling. Unlike other tissues, skeletal muscle fibers exhibited heightened sensitivity to phosphoinositide dynamics, suggesting tissue-specific adaptions that align growth demands with metabolic needs. This insight underscores the lysosome’s broader role as a nutrient-sensing organelle tailored to meet the unique bioenergetic and biosynthetic requirements of muscle physiology. Moreover, these observations may recalibrate current paradigms explaining muscle adaptation during exercise and pathological atrophy.

From a methodological perspective, the team’s integrated approach—combining high-resolution confocal microscopy, lipid mass spectrometry, and CRISPR-Cas9-mediated gene editing—provided an unprecedented window into the spatiotemporal orchestration of lipid turnover and signaling. These techniques illuminated the delicate choreography of lysosomal lipid remodeling happening in real time within intact muscle fibers, an accomplishment that represents a technical tour de force and sets the stage for future mechanistic explorations.

Additionally, the research highlights potential intersections between lysosomal lipid metabolism and other anabolic pathways. The cross-talk between phosphoinositide turnover and autophagic flux, another lysosome-centered process, emerged as a tantalizing area meriting further study. Since autophagy plays a dual role in cell maintenance and remodeling, decoding the interplay between these processes may shed light on muscle plasticity under varying physiological and pathological stresses.

The translational implications are profound. Muscle wasting associated with aging, cachexia, and various chronic diseases remains a significant clinical challenge with limited therapeutic options. The identification of lysosomal phosphoinositide turnover as a critical node upstream of mTORC1 presents novel targets for intervention. Small molecule modulators or gene therapies designed to enhance or restore appropriate lysosomal lipid dynamics could revitalize anabolic signaling pathways and preserve muscle mass and function.

Furthermore, because mTORC1 signaling extends its influence into metabolic regulation, including glucose homeostasis and lipid metabolism, the findings may ripple beyond muscle tissue. Targeting lysosomal lipid turnover might emerge as a multipronged strategy to ameliorate metabolic dysregulations seen in diabetes and obesity. Careful delineation of these systemic effects will be vital.

Importantly, this work challenges the simplistic notion that lysosomes serve merely as end-stage degradation centers. Instead, it aligns with a growing body of evidence positioning lysosomes as versatile signaling hubs where lipid modifications actively regulate cell signaling cascades. This conceptual shift can inspire renewed efforts to characterize lipid dynamics on intracellular membranes across diverse biological contexts.

As muscle strength and mass correlate strongly with healthspan and survival in humans, optimizing muscle anabolic pathways has wide-reaching public health implications. Unlocking the lysosomal lipid code that governs mTORC1 could lead to innovative exercise mimetics or nutritional supplements tailored to augment muscle functionality, particularly in vulnerable populations such as the elderly.

In summary, the work by Picot et al. orchestrates an elegant convergence of cell biology, lipidomics, and muscle physiology to unveil lysosomal phosphoinositide turnover as an indispensable upstream signal for Rag GTPase–mTORC1 activation and muscle growth. It propels lysosomes to center stage as active integrators of nutrient and growth signals, expanding the molecular framework governing muscle anabolism. This landmark discovery not only advances basic scientific knowledge but also charts a promising path toward therapeutic innovation against muscle degeneration.

As the research community digests these insights, future investigations will undoubtedly explore how manipulating lysosomal lipid metabolism could fine-tune mTORC1 outputs across tissues, expand our understanding of lysosomal signaling networks, and ultimately improve muscle health in aging and disease. The marriage of lipid signaling to classical anabolic pathways stands as a testament to the layered complexity of cellular growth control, heralding a new era of metabolic precision medicine.

Subject of Research: Lysosomal phosphoinositide turnover regulation of Rag GTPase–mTORC1 signaling and its impact on muscle growth

Article Title: Lysosomal phosphoinositide turnover acts upstream of RagGTPase–mTORC1 and controls muscle growth

Article References:
Picot, M., Hifdi, N., Vaucourt, M. et al. Lysosomal phosphoinositide turnover acts upstream of RagGTPase–mTORC1 and controls muscle growth. Nat Metab (2026). https://doi.org/10.1038/s42255-026-01484-1

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s42255-026-01484-1

Niemann-Pick disease type C1 is a fatal neurovisceral disorder caused by mutations in the NPC1 gene, leading to the accumulation of cholesterol and various lipids within lysosomes. Patients suffer progressive neurological decline alongside systemic dysfunctions affecting the liver, spleen, and lungs. Despite increasing understanding of disease mechanisms, effective treatments remain elusive. The current study addresses a critical gap by identifying a novel enzyme that regulates BMP metabolism, a lipid class crucial for lysosomal membrane dynamics and function.

BMP lipids are unique anionic phospholipids predominantly enriched within the internal membranes of late endosomes and lysosomes. They play essential roles in membrane curvature, lipid sorting, and the activity of lysosomal hydrolases. Dysregulation of BMP homeostasis has been implicated in several lysosomal disorders; however, enzymes directly responsible for BMP degradation had not been definitively characterized until now. PLA2G15 emerges as a key player, catalyzing BMP hydrolysis and thereby influencing lysosomal lipid equilibrium.

Using a combination of in vitro biochemical assays and in vivo genetic models, the authors confirmed PLA2G15’s BMP hydrolase activity. To investigate therapeutic potential, the team generated PLA2G15 knockout mice and crossed them with the established Npc1^m1N/J mouse model, which recapitulates severe neurological and systemic NPC symptoms. Remarkably, PLA2G15 deficiency in the NPC1 background led to substantial amelioration of hallmark pathological features, indicating a beneficial impact of PLA2G15 inhibition on disease progression.

Disease biomarkers reinforced these observations. Neurofilament light chain (NfL), a well-validated marker of neurodegeneration measured in both cerebrospinal fluid and plasma, was significantly reduced in the double knockout mice compared to NPC1-deficient counterparts. Likewise, serum markers of liver damage, including aspartate aminotransferase (AST) and alanine aminotransferase (ALT), showed marked normalization, reflecting improved hepatic function following PLA2G15 ablation.

Interestingly, while NPC1-deficient mice exhibited increased BMP species, PLA2G15 depletion yielded only minor changes in BMP levels, suggesting nuanced regulation and possible compensatory mechanisms at play. Notably, cholesterol concentrations in brain and liver tissues remained unchanged despite genetic targeting, hinting that the therapeutic improvements stem not from correction of cholesterol accumulation but through modulation of secondary storage lipids.

Secondary lipid species, particularly sphingolipids and alkyl-lysophosphatidylcholine, known to accumulate in NPC1 disease, were significantly reduced in both cerebral and hepatic tissues when PLA2G15 was depleted. This reduction signifies a broader impact on lysosomal lipid metabolism, which may underlie the observed neuroprotective and systemic benefits.

At the cellular level, the study revealed profound rescue of cerebellar Purkinje neurons, a particularly vulnerable population in NPC1 pathology. Histopathological analyses demonstrated increased Purkinje cell survival and notable reductions in astrogliosis, microgliosis, and demyelination throughout the central nervous system. Such neural preservation translates into tangible functional improvements essential for patients’ quality of life.

Supporting the neurological findings, the effect of PLA2G15 deficiency extended to visceral organs. The extent of Kupffer cell hyperplasia within the liver and histiocytic proliferation in the spleen were both diminished. However, certain tissue alterations, such as hepatocyte vacuolation and pulmonary histopathology, remained unaffected, indicating partial organ-specific responses to enzyme inhibition.

Importantly, PLA2G15-deficient mice did not show any adverse lesions in the tissues analyzed, affirming the safety profile of genetic inhibition. Behaviorally, the compound knockout mice exhibited improved neurological composite scores, better motor coordination assessed via rotarod testing, and significantly prolonged survival compared to NPC1-deficient controls, underscoring the robust clinical relevance of targeting PLA2G15.

The authors posit that by attenuating lysosomal BMP hydrolysis, PLA2G15 depletion preserves BMP levels, thereby enhancing lysosomal functionality and reducing lysosomal stress. This effect appears to counteract the secondary lipid burden and cellular toxicity characteristic of lysosomal storage disorders like NPC1. The study’s integration of biochemical, histological, and behavioral data presents a comprehensive framework linking BMP metabolism to disease amelioration.

This work reveals an unprecedented therapeutic strategy for lysosomal diseases whereby targeting lipid metabolism enzymes modulates lysosomal membrane lipid composition and function. Given the centrality of lysosomal dysfunction across numerous neurodegenerative and metabolic disorders, PLA2G15 or its pathway components may represent a wider class of druggable targets beyond NPC1.

Future research will need to dissect the precise molecular mechanisms through which PLA2G15 regulates BMP turnover and to investigate potential small-molecule inhibitors that could replicate the genetic effects observed. Moreover, exploration of PLA2G15’s role across diverse cell types and lysosomal pathologies will illuminate its broader biological relevance and therapeutic potential.

In conclusion, Nyame et al. have uncovered PLA2G15 as a pivotal enzyme in lysosomal BMP metabolism whose genetic inactivation confers striking benefits in a mouse model of Niemann-Pick type C1 disease. This discovery not only advances our understanding of lysosomal lipid homeostasis but also charts a promising path toward novel treatments for devastating lysosomal storage diseases that currently lack effective therapies.

Subject of Research: Lysosomal lipid metabolism and therapeutic targeting in Niemann-Pick disease type C1.

Article Title: PLA2G15 is a BMP hydrolase and its targeting ameliorates lysosomal disease.

Article References:
Nyame, K., Xiong, J., Alsohybe, H.N. et al. PLA2G15 is a BMP hydrolase and its targeting ameliorates lysosomal disease. Nature (2025). https://doi.org/10.1038/s41586-025-08942-y

Image Credits: AI Generated